Key Highlights

  • 35.34% was the gain for Bending Spoons (NASDAQ:BSP), which traded at USD 51.24, about 77% above its USD 29 IPO price, after second-quarter revenue rose 126% to USD 704 million with organic growth of only 3%.
  • 4.44% was the gain for Generate Biomedicines (NASDAQ:GENB), which traded at USD 12.80, about 20% below its USD 16.00 IPO price, with cash of USD 457.4 million expected to fund plans into the first half of 2028.
  • 4.81% was the gain for Scribe Therapeutics (NASDAQ:SCTX), which traded at USD 20.04 on light volume, about 33.6% above its USD 15.00 IPO price, with proceeds expected to fund operations into the first half of 2029.
  • No company announcement dated October 14, 2026 explains any of the three moves; Alamar Biosciences, another 2026 listing, trades about 44% above its USD 17.00 IPO price, so outcomes vary widely among recent listings.

Bending Spoons (NASDAQ:BSP): Largest premium to IPO price

No company announcement dated October 14, 2026 was found, so the 35.34% advance has no stated trigger. The company went public on July 1, 2026 at USD 29, above a marketed range of USD 26 to USD 28, and the shares have since traded well above that level. A recent listing has a short trading history and limited analyst coverage, which can amplify sharp moves in either direction. Shares sold by existing holders, including Baillie Gifford, also meant the offering was not only primary capital. Relative volume of 1.9 times average and a relative strength index of 72.2 describe a strong session, though a move of this size without news can reverse. Bending Spoons reported second-quarter results on August 13, 2026, with adjusted operating income of USD 381 million and third-quarter revenue guidance of USD 733 million to USD 745 million. Most revenue growth came from six acquisitions, so results depend on integrating purchased products. In September the company agreed to buy Miro for USD 1.355 billion in cash. A September 25 release said it syndicated a USD 1.25 billion dollar term loan add-on and a EUR 395 million euro add-on, both due 2031, after Moody's moved its rating to Ba3 from B1 and S&P to BB- from B+. Term loan B debt carries floating interest, so higher benchmark rates would raise interest expense, and the upgrades by Moody's and S&P reflect improved credit quality rather than a lack of leverage. Acquisition integration, leverage and weak organic growth are the main risks, since debt funds purchases that must lift cash flow to pay it down. The Miro purchase is pending, and guidance excludes acquisitions not owned as of August 12.

Generate Biomedicines (NASDAQ:GENB): Trading below the offer

No company announcement dated October 14, 2026 was found, so the 4.44% gain does not trace to a company event. Published market data show the stock opened 2.90% above the prior close. Generate Biomedicines listed after pricing its IPO at USD 16.00 per share, with 25 million shares sold, and the lead program GB-0895 is a long-acting anti-TSLP antibody for severe asthma. With 128,269,428 common shares outstanding at June 30, 2026, the published market capitalization near USD 1.64 billion is consistent with the share price. Generate Biomedicines was incubated by Flagship Pioneering, and its platform uses machine learning to design proteins, with partnerships including Novartis and Amgen that fund part of the research and carry milestone potential. Generate Biomedicines said the SOLAIRIA-1 and SOLAIRIA-2 Phase 3 asthma trials had regulatory approval in 33 of a planned 42 countries, with recruitment under way in six global regions. Research and development expense of USD 64.3 million, up from USD 59.7 million, was driven mainly by those trials, and general and administrative expense rose to USD 13.6 million. Collaboration revenue reflects research work for Amgen and Novartis, and a Novartis program advanced into that company's preclinical pipeline. The company said it will need additional capital for long-term operations, so later equity or partnership funding is plausible. Management said about USD 300 million of IPO proceeds would fund GB-0895 development, which explains why spending on the Phase 3 program is the largest driver of the quarterly loss.

Scribe Therapeutics (NASDAQ:SCTX): Gene editing and cash runway

No company announcement dated October 14, 2026 was found, so the 4.81% gain came on light volume without a stated trigger. Simple arithmetic puts USD 20.04 about 33.6% above the USD 15.00 IPO price. The stock is a recent listing, with trading on the Nasdaq Global Market beginning July 24, 2026 under Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities as joint book-running managers. Newly listed biotech shares often trade on small volume, and early prices can swing on modest orders until a larger holder base forms. Sanofi bought 500,000 shares in a concurrent private placement at the IPO price, and the underwriters exercised their option in full, which signals demand at pricing but does not predict later trading. Scribe Therapeutics reported a second-quarter net loss of USD 6.5 million, compared with USD 9.9 million a year earlier, as research and development expense fell to USD 8.8 million from USD 13.9 million. The per share figure of USD 2.62 reflects a small pre-IPO share count, so it is not comparable with later quarters. STX-1150, an epigenetic silencer of PCSK9 aimed at lowering LDL cholesterol, began first-in-human dosing in Australia in mid-2026, with initial single ascending dose data expected in the first half of 2027. STX-1200 for lipoprotein(a) and STX-1400 for triglycerides are targeted to enter the clinic as early as 2027. Epigenetic silencing aims to switch a gene off without cutting DNA, which could offer a different safety profile from conventional gene editing, although human data are still to come.

Where Things Stand

The answer is that the three recent listings show very different outcomes, with no company announcement dated October 14, 2026 behind any of the moves. Bending Spoons (NASDAQ:BSP) trades far above its IPO price. Scribe Therapeutics (NASDAQ:SCTX) sits above its offer. Generate Biomedicines (NASDAQ:GENB) remains about 20% below. Short trading histories and thin coverage amplify swings. Each company reports third-quarter results, with dates to be announced. This is not investment advice.